De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Ardelyx Beheer

Beheer criteriumcontroles 2/4

De CEO Ardelyx's is Mike Raab, benoemd in Mar2009, heeft een ambtstermijn van 15.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.12M, bestaande uit 17% salaris en 83% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.53% van de aandelen van het bedrijf, ter waarde MX$ 146.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 8.9 jaar.

Belangrijke informatie

Mike Raab

Algemeen directeur

US$4.1m

Totale compensatie

Percentage CEO-salaris	17.0%
Dienstverband CEO	15.5yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	8.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mike Raab's beloning veranderd ten opzichte van Ardelyx's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$66m
Dec 31 2023	US$4m	US$700k	-US$66m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$56m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$2m	US$650k	-US$67m
Sep 30 2022	n/a	n/a	-US$114m
Jun 30 2022	n/a	n/a	-US$135m
Mar 31 2022	n/a	n/a	-US$153m
Dec 31 2021	US$4m	US$650k	-US$158m
Sep 30 2021	n/a	n/a	-US$151m
Jun 30 2021	n/a	n/a	-US$125m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$4m	US$633k	-US$94m
Sep 30 2020	n/a	n/a	-US$85m
Jun 30 2020	n/a	n/a	-US$91m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$2m	US$595k	-US$95m
Sep 30 2019	n/a	n/a	-US$103m
Jun 30 2019	n/a	n/a	-US$104m
Mar 31 2019	n/a	n/a	-US$100m
Dec 31 2018	US$4m	US$575k	-US$91m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$555k	-US$64m

Compensatie versus markt: De totale vergoeding ($USD 4.12M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 870.10K ).

Compensatie versus inkomsten: De vergoeding van Mike is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mike Raab (59 yo)

15.5yrs

Tenure

US$4,118,144

Compensatie

Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019 and its Chairman...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Raab	President	15.5yrs	US$4.12m	0.53% MX$ 146.2m
Elizabeth Grammer	Chief Legal & Administrative Officer and Secretary	10.3yrs	US$1.63m	0.082% MX$ 22.6m
Laura Williams	Chief Medical Officer	3.8yrs	US$1.63m	0.13% MX$ 36.9m
Justin Renz	Chief Financial & Operations Officer	4.3yrs	US$1.73m	0.13% MX$ 34.6m
Robert Felsch	Senior VP of Finance & Chief Accounting Officer	2.5yrs	geen gegevens	0.039% MX$ 10.7m
Caitlin Lowie	Vice President of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Mike Kelliher	Executive Vice President of Corporate Development & Strategy	less than a year	geen gegevens	geen gegevens
Charon Spencer	Chief Human Resources Officer	1.7yrs	geen gegevens	geen gegevens
David Rosenbaum	Chief Development Officer	9.7yrs	US$1.63m	0.25% MX$ 68.7m
Robert Blanks	Chief Regulatory Affairs & Quality Assurance Officer	no data	US$1.70m	0.14% MX$ 37.5m
Susan Rodriguez	Advisor	4.3yrs	US$1.04m	0.19% MX$ 52.7m
Kimia Keshtbod	Manager of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ARDX * wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Raab	President	15.5yrs	US$4.12m	0.53% MX$ 146.2m
David Mott	Independent Chairman of the Board	15.5yrs	US$249.90k	0.51% MX$ 141.9m
William C. Bertrand	Independent Director	8.9yrs	US$214.90k	0.098% MX$ 27.0m
Richard Rodgers	Independent Director	10.5yrs	US$222.40k	0.11% MX$ 29.4m
Robert Bazemore	Independent Director	8.3yrs	US$202.40k	geen gegevens
Onaiza Cadoret-Manier	Independent Director	4.5yrs	US$199.90k	0.047% MX$ 12.9m
Muna Bhanji	Independent Director	3.5yrs	US$202.40k	0.041% MX$ 11.2m

8.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARDX * wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.9 jaar).

Ardelyx Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Insufficient new directors

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Insufficient new directors

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Recent updates

Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Forecast breakeven date pushed back to 2026

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Insufficient new directors

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Insufficient new directors

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Ardelyx, Inc. announced that it has received $50 million in funding

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Insufficient new directors

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

New major risk - Shareholder dilution

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.03 (vs US$0.14 loss in 3Q 2022)

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.21 loss in 1Q 2022)

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd